Product image of Lecigimon (Entacapone, Levodopa, Carbidopa Monohydrate) supplied by GNH India

Lecigimon

Active Ingredient:
Entacapone, Levodopa, Carbidopa Monohydrate
Origin:
EU

Lecigimon (Entacapone, Levodopa, Carbidopa Monohydrate)

Entacapone, Levodopa, Carbidopa Monohydrate, the active ingredients in Lecigimon, are a dopamine precursor/COMT inhibitor combination presented as a fixed‑dose oral tablet for intestinal use. It is indicated for the management of Parkinson's disease symptoms in adult patients.
GNH India supplies Lecigimon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Lobsor Pharmaceuticals Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lecigimon is used within the Parkinson's disease therapeutic pathway to improve motor control and reduce off‑periods.

  • Parkinson's disease: enhances dopaminergic stimulation to improve tremor, rigidity and bradykinesia.
  • Parkinson's disease with motor fluctuations: prolongs levodopa plasma half‑life, helping to smooth symptom control.
  • Advanced Parkinson's disease: provides combined levodopa delivery with peripheral decarboxylase and COMT inhibition to maintain consistent central dopamine levels.

How It Works

  • Lecigimon delivers levodopa, a dopamine precursor, while carbidopa blocks peripheral aromatic L‑amino acid decarboxylase, increasing central levodopa availability. Entacapone inhibits catechol‑O‑methyltransferase (COMT), reducing peripheral levodopa metabolism and extending its plasma half‑life, resulting in sustained dopaminergic stimulation in the brain.

Side Effects

Lecigimon may cause a range of adverse reactions.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Dizziness: often related to orthostatic changes.
  • Headache: transient and usually resolves.
  • Insomnia: difficulty initiating or maintaining sleep.
  • Orthostatic hypotension: drop in blood pressure upon standing.
  • Dry mouth: reduced salivation.

Serious or Rare Side Effects

  • Severe hypotension: marked blood pressure decline requiring medical attention.
  • Hallucinations or psychosis: visual or auditory disturbances.
  • Dyskinesia: involuntary movements due to excess central dopamine.
  • Hepatic enzyme elevation: abnormal liver function tests.
  • Neuroleptic malignant syndrome: rare but life‑threatening reaction.

Precautions & Warnings

Before initiating Lecigimon, clinicians should consider several safety measures.

  • Blood pressure monitoring: watch for orthostatic changes, especially after dose adjustments.
  • Hepatic function assessment: evaluate liver enzymes periodically.
  • Psychiatric evaluation: monitor for hallucinations or mood alterations.
  • Renal impairment dosing: adjust dose in patients with reduced kidney function.
  • Concomitant MAO‑B inhibitors: avoid co‑administration to prevent hypertensive crises.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Lecigimon can interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

  • Non‑selective MAO inhibitors: risk of hypertensive crisis.
  • Alpha‑adrenergic blockers: may cause severe hypotension.
  • Antipsychotics (especially dopamine antagonists): can diminish therapeutic effect.

Moderate Interactions (Monitor Closely)

  • SSRIs and SNRIs: increased risk of serotonin syndrome.
  • Other dopaminergic agents: may exacerbate dyskinesia.
  • Diuretics: enhance orthostatic hypotension.
  • NSAIDs: potential for gastrointestinal irritation when combined with levodopa.

Frequently Asked Questions

Lecigimon is prescribed to manage the motor symptoms of Parkinson's disease, including tremor, rigidity, and bradykinesia, and to reduce motor fluctuations that can occur with levodopa therapy.

Levodopa serves as a dopamine precursor that crosses the blood‑brain barrier. Carbidopa inhibits peripheral aromatic L‑amino acid decarboxylase, increasing the amount of levodopa that reaches the brain. Entacapone blocks catechol‑O‑methyltransferase (COMT), slowing levodopa breakdown and extending its plasma half‑life, resulting in more stable dopamine levels.

The specific dose of Lecigimon is individualized by the prescribing clinician based on the patient’s disease stage, response to therapy, and tolerability. Dosage adjustments are made to achieve optimal symptom control while minimizing side effects.

Safety data for Lecigimon in pregnancy and lactation are limited. The product’s pregnancy category is unknown, and it should only be used if the potential benefit justifies any potential risk to the fetus or infant. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lecigimon combines levodopa, carbidopa, and entacapone in a single tablet, offering the convenience of a fixed‑dose regimen. Compared with levodopa/carbidopa alone, the addition of entacapone prolongs levodopa’s effect, reducing off‑periods. It provides a similar therapeutic outcome to separate administration of the three agents but with fewer pills.

Lecigimon tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Lecigimon is taken orally, usually with food to reduce gastrointestinal irritation. The tablet is swallowed whole with a glass of water. Dosing frequency and timing are determined by the prescriber to match the patient’s symptom pattern.

Serious risks include severe hypotension, hallucinations or psychosis, dyskinesia, and rare hepatic enzyme elevations. Patients should be monitored for sudden changes in blood pressure, mental status, or abnormal liver function tests, and any concerning symptoms should be reported promptly.

Lecigimon is contraindicated in patients taking non‑selective MAO inhibitors, those with known hypersensitivity to any component, and individuals with severe hepatic impairment. Caution is also advised for patients with a history of cardiac arrhythmias or uncontrolled hypertension.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Entacapone, Levodopa, Carbidopa Monohydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT